Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis.

ABSTRACT: Rheumatoid arthritis (RA) is a chronic inflammatory disease with fluctuating course of progression. Despite substantial improvement in treatments in recent years, treatment response is still not guaranteed. The aim of this study was to identify variation in Disease Activity Score 28 (DAS28) of RA patients in response to Tocilizumab, and to investigate both molecular and clinical factors influencing response. Clinical and biochemical data for 485 RA patients receiving Tocilizumab in combination with methotrexate were extracted from the LITHE phase III clinical study (NCT00106535), and post-hoc analysis conducted. Latent class mixed models were used to identify statistically distinct trajectories of DAS28 after the initiation of treatment. Biomarker measurements were then analysed cross-sect

SUBMITTER: Blair JPM 

PROVIDER: S-EPMC7434906 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature